The Claim
In 3T3-L1 adipocytes, pharmacological inhibition of SIRT1 using EX527 reduces ATGL expression and lipolysis, and co-treatment with resveratrol restores both ATGL expression and lipolysis, demonstrating that the SIRT1/FOXO1/ATGL pathway directly regulates fat breakdown in this cell line.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In fat cells grown in the lab, blocking SIRT1 decreases the production of ATGL and the breakdown of fat, and adding resveratrol reverses this effect, showing that SIRT1, FOXO1, and ATGL work together to control fat breakdown in these cells.
See the scientific wording
In 3T3-L1 adipocytes, inhibition of SIRT1 with EX527 suppresses ATGL expression and lipolysis, which can be reversed by resveratrol, confirming the SIRT1/FOXO1/ATGL pathway’s role in regulating fat breakdown.
When SIRT1 is active, it removes acetyl groups from FOXO1, allowing FOXO1 to bind to the ATGL gene and turn it on. ATGL then breaks down stored fat into free fatty acids. If SIRT1 is blocked, FOXO1 stays acetylated and cannot activate ATGL, so fat breakdown stops. Adding resveratrol reactivates SIRT1, restoring FOXO1 activity, ATGL production, and fat breakdown.
What the research says
1 studyIn lab-grown fat cells, blocking SIRT1 stops fat breakdown, but adding resveratrol fixes it — proving SIRT1 is needed to burn fat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.